These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36142807)

  • 1. Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells.
    Cappabianca L; Sebastiano M; Ruggieri M; Sbaffone M; Zelli V; Farina AR; Mackay AR
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characterization and Inhibition of a Novel Stress-Induced Mitochondrial Protecting Role for Misfolded TrkAIII in Human SH-SY5Y Neuroblastoma Cells.
    Cappabianca L; Ruggieri M; Sebastiano M; Sbaffone M; Martelli I; Ruggeri P; Di Padova M; Farina AR; Mackay AR
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Alternative TrkAIII Splice Variant, a Targetable Oncogenic Participant in Human Cutaneous Malignant Melanoma.
    Cappabianca L; Zelli V; Pellegrini C; Sebastiano M; Maccarone R; Clementi M; Chiominto A; Ruggeri P; Cardelli L; Ruggieri M; Sbaffone M; Fargnoli MC; Guadagni S; Farina AR; Mackay AR
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells.
    Farina AR; Tacconelli A; Cappabianca L; Cea G; Chioda A; Romanelli A; Pensato S; Pedone C; Gulino A; Mackay AR
    Oncogene; 2009 Nov; 28(46):4075-94. PubMed ID: 19734938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.
    Gneo L; Ruggeri P; Cappabianca L; Farina AR; Di Ianni N; Mackay AR
    Oncotarget; 2016 Dec; 7(49):80820-80841. PubMed ID: 27821809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
    Farina AR; Cappabianca L; Ruggeri P; Gneo L; Pellegrini C; Fargnoli MC; Mackay AR
    J Exp Clin Cancer Res; 2018 Jun; 37(1):119. PubMed ID: 29914559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
    Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD2 expression and activity at the mitochondria, within the context of a tumour stem cell-like phenotype.
    Ruggeri P; Farina AR; Di Ianni N; Cappabianca L; Ragone M; Ianni G; Gulino A; Mackay AR
    PLoS One; 2014; 9(4):e94568. PubMed ID: 24736663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity.
    Farina AR; Cappabianca L; Ruggeri P; Gneo L; Maccarone R; Mackay AR
    Oncotarget; 2015 Nov; 6(34):35636-51. PubMed ID: 26415233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.
    Tacconelli A; Farina AR; Cappabianca L; Desantis G; Tessitore A; Vetuschi A; Sferra R; Rucci N; Argenti B; Screpanti I; Gulino A; Mackay AR
    Cancer Cell; 2004 Oct; 6(4):347-60. PubMed ID: 15488758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TrkAIII promotes microtubule nucleation and assembly at the centrosome in SH-SY5Y neuroblastoma cells, contributing to an undifferentiated anaplastic phenotype.
    Farina AR; Di Ianni N; Cappabianca L; Ruggeri P; Ragone M; Ianni G; Gulino A; Mackay AR
    Biomed Res Int; 2013; 2013():740187. PubMed ID: 23841091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.
    Farina AR; Tacconelli A; Cappabianca L; Cea G; Panella S; Chioda A; Romanelli A; Pedone C; Gulino A; Mackay AR
    Mol Cell Biol; 2009 Sep; 29(17):4812-30. PubMed ID: 19564412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma.
    Tacconelli A; Farina AR; Cappabianca L; Gulino A; Mackay AR
    Future Oncol; 2005 Oct; 1(5):689-98. PubMed ID: 16556046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation.
    Farina AR; Cappabianca L; Gneo L; Ruggeri P; Mackay AR
    Oncotarget; 2018 Feb; 9(9):8368-8390. PubMed ID: 29492201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TrkAIII. A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance.
    Tacconelli A; Farina AR; Cappabianca L; Gulino A; Mackay AR
    Cell Cycle; 2005 Jan; 4(1):8-9. PubMed ID: 15611661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery, characterization and potential roles of a novel NF-YAx splice variant in human neuroblastoma.
    Cappabianca L; Farina AR; Di Marcotullio L; Infante P; De Simone D; Sebastiano M; Mackay AR
    J Exp Clin Cancer Res; 2019 Dec; 38(1):482. PubMed ID: 31805994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
    Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Study of Alternative TrkA Splicing Identifies TrkAIII as a Novel Potentially Targetable Participant in PitNET Progression.
    Sbaffone M; Jaffrain-Rea ML; Cappabianca L; Carbonara F; Gianno F; Feola T; Ruggieri M; Zelli V; Maccarone R; Guadagni S; Clementi M; Arcella A; Esposito V; Carozza G; Martelli I; Farina AR; Mackay AR
    Biology (Basel); 2024 Mar; 13(3):. PubMed ID: 38534441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TrkAIII expression in the thymus.
    Tacconelli A; Farina AR; Cappabianca L; Cea G; Panella S; Chioda A; Gallo R; Cinque B; Sferra R; Vetuschi A; Campese AF; Screpanti I; Gulino A; Mackay AR
    J Neuroimmunol; 2007 Feb; 183(1-2):151-61. PubMed ID: 17241672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.
    Hopkins-Donaldson S; Yan P; Bourloud KB; Muhlethaler A; Bodmer JL; Gross N
    Oncogene; 2002 Sep; 21(39):6132-7. PubMed ID: 12203125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.